Belite Bio, Inc (BLTE): Cash & Equivalents
$352.93M
As of 2025-12-31
+103.2%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $352.93M | n/m | 2026-03-31, Balance as of period end |
| 2024-12-31 | $31.68M | -64.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $88.16M | +109.5% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $42.09M | +142.7% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $17.34M | n/a | 2023-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | $352.93M | n/m |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $85.72M | -4.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $74.88M | +61.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $91.14M | -52.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗